Examples of new therapeutic approaches from the NGFN

  • In lung cancer crucial mutations have been identified which led to the initiation of multiple clinical studies: A Phase-II study with Dasatinib (Tyrosinkinase-Inhibitor, currently applied in the leukemia treatment) in the not-small cellular bronchial carcinoma. An at numerous centers worldwide conducted Phase-I study with FGFR1-inhibitors in patients with FGFR1-amplified bronchial carcinoma. A Phase-I study with the combination HSP90 inhibitor and ERBB2 antibody in patients with ERBB2-mutation or amplification.

  • Defects in glucose-transporter Type 1 have been identified as (frequent) cause of epilepsy and a remedy has been found in food with high fat content. These findings have significantly influenced diagnostics, clinical management and therapy over the last five years. Children with severe pharmaceutical-resistant epilepsies and certain diseases of the musculoskeletal system, when put under a ketogenic diet, get free of epileptic seizures (or only minor afflictions remain). Children with cognitive impairments and moderate mental retardation experience a dramatic amelioration and often a considerably improved school performance.

  • Most of the disease genes responsible for the inflammatory intestinal disease Morbus Crohn had been chronicled by the NGFN in a very detailed risk index (163 disease genes). The functional monitoring has shown similarities in the pathophysiological metabolic pathways of numerous chronic inflammatory diseases of the barrier organs (intestine, skin, lungs). This is a good example for the necessity of interdisciplinary approaches. Due to the NGFN knowledge in this field, two drugs are being developed currently at the CONARIS Research Institute AG. Together with an industry partner, a biotechnological agent is being led through phase I, a Small Molecule will be in phase I in 2014.

  • NGFN scientists have shown the influence of cholesterol-lowering drugs on Alzheimer’s disease. They have found that the percentage of potentially deleterious amyloid beta-peptides in the brain liquid in Alzheimer’s patients is declining after treatment with statin or food rich with omega-3 fatty acids. On this basis, a medical food product based on fatty acids had been developed and is already available commercially. Up to now, two studies for early phases had been completed. Presently a longitudinal analysis is being conducted as EU FP7 Lipididiet project.

INTRANET (Members login)